Lactucopicrin promotes the autophagic degradation of MAP2K4/MKK4 by mediating CCDC50 palmitoylation to alleviate osteoarthritis progression

Read full text
Authors: Wenjun Li, Qijie Sun, Konghe Hu, Dongmei Tang, Cheng Yang, Yingchao Xie, Xiaodong Peng, Yi Deng, Jiansen Lu, Yong Qi, Yifen Lin, Hongtao Sun
+4 more Qinyu Tian, Changpeng Xu, Xinggui Tian, Huaji Jiang
Cited by: 2
References: 43

Abstract

Macroautophagy/autophagy plays a crucial role in maintaining cellular homeostasis and protecting against osteoarthritis (OA). Its dysregulation contributes to OA progression by promoting chondrocyte senescence, inflammation, and cartilage degradation. Enhancing autophagic activity thus represents a promising therapeutic strategy for OA. In this study, we identified lactucopicrin (LCP) as an effective autophagy activator that alleviates OA progression in a mouse model induced by the destabilization of the medial meniscus, by reducing cartilage degeneration and preserving matrix integrity. Mechanistically, LCP enhances ZDHHC4-catalyzed palmitoylation of the cargo receptor CCDC50, facilitating the selective autophagic degradation of MAP2K4/MKK4, leading to the suppression of MAPK/JNK signaling and the attenuation of chondrocyte senescence. Structural analysis reveals that LCP directly binds to His72 of ZDHHC4 via its p-hydroxybenzoic acid moiety, boosting enzymatic activity and promoting selective autophagy. These findings establish a novel ZDHHC4-CCDC50-MAP2K4/MKK4-MAPK/JNK regulatory axis linking palmitoylation, autophagy, and senescence, and identify LCP as a promising agent for targeting this pathway to inhibit OA progression. Furthermore, this study provides mechanistic insights into the crosstalk between autophagy, protein palmitoylation, and cellular senescence in degenerative joint disease.Abbreviation: ABE: acyl-biotin exchange; ADAMTS5: ADAM metallopeptidase with thrombospondin type 1 motif 5; CCDC50: coiled-coil domain containing 50; COL2A1: collagen, type II, alpha 1; COL10A1: collagen, type X, alpha 1; DARTS: drug affinity responsive target stability; DHHC: Asp-His-His-Cys catalytic motif; GOT1/AST: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALT: glutamic pyruvic transaminase, soluble; H2O2: hydrogen peroxide; LCP: lactucopicrin; IL6: interleukin 6; MAPK/JNK: mitogen-activated protein kinase; MAP2K4/MKK4: mitogen-activated protein kinase kinase 4; MMP13: matrix metallopeptidase 13; OA: osteoarthritis; p-MAPK/JNK: phosphorylated mitogen-activated protein kinase; SASP: senescence-associated secretory phenotype; SA-GLB1/β-gal: senescence-associated galactosidase, beta 1; ZDHHC: zinc finger, DHHC domain containing.

Fields of Study & Subjects

Osteoarthritis Treatment and Mechanisms Autophagy in Disease and Therapy Rheumatoid Arthritis Research and Therapies

Publication details

Journal / source
Autophagy
Publisher
Informa UK Limited
Volume
22
Issue
3
Pages
526–544
Publication date
21 January 2026
Language
EN